Lilly's Cyramza gets first EU CHMP nod
This article was originally published in Scrip
Executive Summary
Lilly's novel targeted anticancer Cyramza (ramucirumab) is set for EU approval in its first indications, in stomach cancer, following a positive opinion from the CHMP at its latest meeting.